Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
US-12559562-B2 · Feb 24, 2026 · US
This page is not indexed by search engines while we improve data quality.
Okada Hideho patents
Okada Hideho is listed as an inventor on 40 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Okada Hideho |
| Total patents | 40 |
| First publication | Sep 17, 2015 |
| Latest publication | Feb 24, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
H3.3 ctl peptides and uses thereof
US-2025090636-A1 · Mar 20, 2025 · US
Methods of treating egfrviii expressing glioblastomas
US-2025034229-A1 · Jan 30, 2025 · US
Methods of treating EGFRvIII expressing glioblastomas
US-12144826-B2 · Nov 19, 2024 · US
Methods of treating glioblastomas
US-2024325449-A1 · Oct 3, 2024 · US
Methods of treating glioblastomas
US-12090170-B2 · Sep 17, 2024 · US
Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
US-2024252608-A1 · Aug 1, 2024 · US
TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR
US-2024238396-A1 · Jul 18, 2024 · US
H3.3 CTL peptides and uses thereof
US-11925679-B2 · Mar 12, 2024 · US
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
US-11865167-B2 · Jan 9, 2024 · US
Recent patents
Latest publications not already listed above.
Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
US-11723963-B2 · Aug 15, 2023 · US
Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
US-2023055337-A1 · Feb 23, 2023 · US
Use of mog for priming a treatment for glioblastoma
US-2022378832-A1 · Dec 1, 2022 · US
T-cell receptors and methods of use thereof
US-2022273714-A1 · Sep 1, 2022 · US
H3.3 ctl peptides and uses thereof
US-2022118069-A1 · Apr 21, 2022 · US
H3.3 CTL peptides and uses thereof
US-11185577-B2 · Nov 30, 2021 · US
Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US-2021338790-A1 · Nov 4, 2021 · US
Mutant IDH1 Specific T Cell Receptor
US-2021087252-A1 · Mar 25, 2021 · US
H3.3 ctl peptides and uses thereof
US-2021038704-A1 · Feb 11, 2021 · US
Trans-antigen targeting in heterogeneous cancers and methods of use thereof
US-2021023136-A1 · Jan 28, 2021 · US
Methods of treating glioblastomas
US-2021023139-A1 · Jan 28, 2021 · US
Methods of treating egfrviii expressing glioblastomas
US-2021023138-A1 · Jan 28, 2021 · US
Methods for treating brain cancer using il-13r alpha 2 peptide-based compositions
US-10874730-B2 · Dec 29, 2020 · US
H3.3 CTL peptides and uses thereof
US-10849965-B2 · Dec 1, 2020 · US
Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
US-2020246442-A1 · Aug 6, 2020 · US
Method for treating brain tumors
US-10617667-B2 · Apr 14, 2020 · US
H3.3 CTL Peptides and Uses Thereof
US-2020101148-A1 · Apr 2, 2020 · US
H3.3 CTL Peptides and Uses Thereof
US-2020009236-A1 · Jan 9, 2020 · US
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US-2019330356-A1 · Oct 31, 2019 · US
H3.3 CTL peptides and uses thereof
US-10441644-B2 · Oct 15, 2019 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Univ California | 23 |
| Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education | 7 |
| Novartis Ag | 6 |
| Univ Pennsylvania | 6 |
| Univ Pittsburgh Commonwealth Sys Higher Education | 4 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 32 |
| A61K40/11 | 31 |
| A61K2239/47 | 31 |
| A61K2239/31 | 23 |
| A61K2239/38 | 22 |